A novel CDC25B promoter-based oncolytic adenovirus inhibited growth of orthotopic human pancreatic tumors in different preclinical models

Clinical Cancer Research

Volumn 21, Issue 7, 2015, Pages 1665-1674

  Weber, Helga L ^a,b   Gidekel, Manuel ^b,c   Werbajh, Santiago ^a   Salvatierra, Edgardo ^a   Rotondaro, Cecilia ^a   Sganga, Leonardo ^a   Haab, Gabriela Acosta ^d   Curiel, David T ^e   Cafferata, Eduardo G ^a   Podhajcer, Osvaldo L ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

^c UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^d Hospital de Oncología M Curie   (Argentina)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CDC25B PHOSPHATASE; GELATINASE B; GEMCITABINE; ONCOLYTIC ADENOVIRUS; PHOSPHATASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; PROTEIN TYROSINE PHOSPHATASE;

ADENOVIRIDAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; DRUG PENETRATION; ENZYME ACTIVITY; ESSENTIAL GENE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PSEUDOTYPING; SEROTYPE; SYRIAN HAMSTER; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG SCREENING; GENETICS; HAMSTER; MESOCRICETUS; PANCREATIC NEOPLASMS; PROCEDURES;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CDC25 PHOSPHATASES; CRICETINAE; DEOXYCYTIDINE; HUMANS; MESOCRICETUS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927603439     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2316     Document Type: Article

References (40)

1. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009;6:412-22.
2. Guse K, Hemminki A. Cancer gene therapy with oncolytic adenoviruses. J BUON 2009;14 Suppl 1:S7-15.
3. Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP 2006;7:349-60.
4. Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther 2010;3:111-27.
5. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010;18:243-50.
6. Nelson AR, Davydova J, Curiel DT, Yamamoto M. Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci 2009;100:2181-7.
7. Onimaru M, Ohuchida K, Mizumoto K, Nagai E, Cui L, Toma H, et al. hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells. Cancer Sci 2010;101:735-42.
8. Onimaru M, Ohuchida K, Nagai E, Mizumoto K, Egami T, Cui L, et al. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Lett 2010; 294:178-86.
9. Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Hallden G. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther 2011;18:734-43.
10. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX- 015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9:555-61.
11. Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther 2011;18:167-75.
12. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-47.
13. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004;11:1043-51.
14. Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, et al. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 2004;23:71-81.
15. Tang J, Hu M, Lee S, Roblin R. Primer mixture enhances PCR detection of Mycoplasma/Acholeplasma contaminants in cell cultures. In Vitro Cell Dev Biol Anim 1999;35:1-3.
16. Cafferata EG, Maccio DR, Lopez MV, Viale DL, Carbone C, Mazzolini G, et al. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models. Clin Cancer Res 2009;15:3037-49.
17. Lopez MV, Viale DL, Cafferata EG, Bravo AI, Carbone C, Gould D, et al. Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses. PLoS ONE 2009;4:e5119.
18. Bouvet M, Wang J, Nardin SR, Nassirpour R, Yang M, Baranov E, et al. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res 2002;62:1534-40.
19. Harada H, Kizaka-Kondoh S, Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 2005;4:182-93.
20. Korner K, Jerome V, Schmidt T, Muller R. Cell cycle regulation of the murine cdc25B promoter: essential role for nuclear factor-Y and a proximal repressor element. J Biol Chem 2001;276:9662-9.
21. Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011;17:867-97.
22. Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, et al. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 2009;15:3396-405.
23. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011;60:861-8.
24. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
25. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008;14:5995-6004.
26. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 2011;17:5793-800.
27. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-6.
28. Lee WP, Tai DI, Tsai SL, Yeh CT, Chao Y, Lee SD, et al. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res 2003;63:6229-36.
29. Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, Thomsen KM, et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 2009;13:2050-8.
30. Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am 1990;19:793-810.
31. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002;36:S57-64.
32. Cascante A, Abate-Daga D, Garcia-Rodriguez L, Gonzalez JR, Alemany R, Fillat C. GCV modulates the antitumoural ef ficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model. Gene Ther 2007;14:1471-80.
33. Toyoda E, Doi R, Kami K, Mori T, Ito D, Koizumi M, et al. Midkine promoter-based conditionally replicative adenovirus therapy for midkine- expressing human pancreatic cancer. J Exp Clin Cancer Res 2008;27:30.
34. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine- induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res 2009;15:1730-40.
35. Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003;125:1203-18.
36. Huch M, Gros A, Jose A, Gonzalez JR, Alemany R, Fillat C. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia 2009;11:518-28.
37. Ramirez PJ, Vickers SM, Ono HA, Davydova J, Takayama K, Thompson TC, et al. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am J Surg 2008;195:481-90.
38. Shirley LA, Aguilar LK, Aguilar-Cordova E, Bloomston M, Walker JP. Therapeutic endoscopic ultrasonography: intratumoral injection for pancreatic adenocarcinoma. Gastroenterol Res Pract 2013;2013:207129.
39. Jose A, Sobrevals L, Miguel Camacho-Sanchez J, HuchM, Andreu N, Ayuso E, et al. Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts. Oncotarget 2013;4:94-105.
40. Bolontrade MF, Sganga L, Piaggio E, Viale DL, Sorrentino MA, Robinson A, et al. A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus. Stem Cells Dev 2012;21:2689-702.